FDA Clearance Tracker · DEN180041
Monarch eTNS System
Last checked: Nov 20, 2026Latest source record: Apr 19, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Apr 19, 2019
De Novo granted
Time to decision
263 days
Received Jul 30, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN180041
- Device name
- Monarch eTNS System
- Applicant
- Neurosigma, Inc.
- Applicant location
- Los Angeles, CA
- Received
- Jul 30, 2018
- Decided
- Apr 19, 2019
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5898
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN180041
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Neurosigma, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233293 · Decided Jan 16, 2024 · 109 days after receipt
Device type: Transcutaneous Nerve Stimulator For Adhd (QGL) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.